The five-year study between Health Innovation Manchester and US pharmaceutical company Lilly will evaluate the real-world effectiveness of tirzepatide in weight loss, diabetes prevention and prevention of obesity-related complications for adults with obesity.

Mayor of Greater Manchester, Andy Burnham, said: ‘Greater Manchester is world-renowned as a hub for innovation in health and life sciences. The results of the trial announced today could have a far-reaching impact on how we treat obesity globally, and our city-region is ready to make a significant contribution through our outstanding health data assets, R&D expertise, and the strong partnerships between industry, universities and public sector organisations.'

The five-year study will also aim to collect data on healthcare resource utilisation, health-related quality of life and changes in participants' employment status and sick days from work.